BioMaPS Institute for Quantitative Biology

Porton Advanced Announces a Strategic Partnership with BioMap, with AI Models Facilitating AAV Gene Therapy Development

Retrieved on: 
Mercredi, novembre 8, 2023
Vivisection, AAV, Health, Biotechnology, CDMO, Research, R, Senior, Partnership, AI, BioMaPS Institute for Quantitative Biology, Vaccine

BioMap will leverage Porton Advanced's unique Adeno-Associated Virus (AAV) vector technology platform and research data to develop AAV assembly efficiency models and an assembly distribution model.

Key Points: 
  • BioMap will leverage Porton Advanced's unique Adeno-Associated Virus (AAV) vector technology platform and research data to develop AAV assembly efficiency models and an assembly distribution model.
  • The goal is to harness the power of large-scale life science models, accelerating the design of AAV vectors, and expanding the application of AI models in the field of gene therapy.
  • However, the limitations of natural serotype AAVs in satisfying clinical needs have stimulated scientists' interest in fostering innovative AAV development through AI technology, especially AI models.
  • Dr. Yangzhou Wang, CEO of Porton Advanced, commented, "We are very excited to cooperate with BioMap to provide better solutions for gene therapy research by using AI models.

BioMap Establishes a Strategic Collaboration with Sanofi to Co-Develop AI Modules to Accelerate Drug Discovery for Biotherapeutics

Retrieved on: 
Mardi, octobre 10, 2023
Technology, Nanotechnology, Health Technology, Software, Biotechnology, Hardware, Health, Pharmaceutical, Artificial Intelligence, Multimedia, Data science, Addendum (research platform), Drug development, Intelligence, Biology, Automation, AI, Protein engineering, Neurology, Collection, BioMaPS Institute for Quantitative Biology, Rare, Research, Protein, Drug discovery, Medical device, Fine chemical, Sanofi

BioMap announced today a groundbreaking strategic collaboration with Sanofi to co-develop cutting-edge AI modules for biotherapeutic drug discovery leveraging BioMap’s AI platform.

Key Points: 
  • BioMap announced today a groundbreaking strategic collaboration with Sanofi to co-develop cutting-edge AI modules for biotherapeutic drug discovery leveraging BioMap’s AI platform.
  • View the full release here: https://www.businesswire.com/news/home/20231010485897/en/
    With the power of BioMap's foundational life science models, researchers can innovate in various phases of the drug discovery and development process, including target discovery, molecular design, and optimization.
  • BioMap’s foundational models are revolutionizing AI in biology by enabling one large model, trained on ubiquitous unlabeled data, to inform multiple downstream task models.
  • BioMap will be eligible to receive payments of over $1 billion based on achievement of pre-clinical development, clinical development, regulatory, and commercial milestones.

BRV China-Backed HPC-AI Tech Completes $6 Million Seed and Angel Round Financing

Retrieved on: 
Mercredi, septembre 14, 2022
Collaboration, Star, Robotics, BRV, Lightspeed Venture Partners, Ecology, Industry, GitHub, Conifer cone, RMB, PPTV, Solution, Cloud computing, Transport, Technology, Artificial intelligence, Preqin, Research, AI, Waterdrop, BioMaPS Institute for Quantitative Biology, Medical device, USD, Silicon

BEIJING, Sept. 14, 2022 /PRNewswire/ -- HPC-AI Tech, an artificial intelligence high-performance optimization platform, recently closed $6 million seed and angel rounds, with BlueRun Ventures China (BRV China) acting as the lead investor for the angel round.

Key Points: 
  • BEIJING, Sept. 14, 2022 /PRNewswire/ -- HPC-AI Tech, an artificial intelligence high-performance optimization platform, recently closed $6 million seed and angel rounds, with BlueRun Ventures China (BRV China) acting as the lead investor for the angel round.
  • Founded in Beijing in 2021, HPC-AI Tech has established an overseas R&D center in Singapore and is focused on the enterprise AI market.
  • Colossal-AI efficiently promotes the application of large AI models on the ground and helps enterprises achieve low-cost AI intelligent solutions.
  • "As an early-stage investor of HPC-AI Tech, BRV China is pleased to see that HPC-AI Tech has been recognized by many users in terms of its product development and global open source ecology.

Data Showing MyMD Pharmaceuticals’ MYMD-1® May Extend Life and Improve Health Published in the Journal of Gerontology: Biological Sciences

Retrieved on: 
Mercredi, août 3, 2022
FDA, Health, Clinical Trials, Research, Pharmaceutical, Science, IL-6, Hospital, Autoimmunity, Mouse, COVID-19, Inflammation, TNF, MS, Annual report, The Journals of Gerontology, Life, Pathology, Epilepsy, Cox, Disability, Degenerative disease, Frailty, Company, Chronic pain, MPH, CNS, Nasdaq, Biomarker, Ageing, FDA, Maintenance, BioMaPS Institute for Quantitative Biology, Disease, Metformin, Journal, Thyroiditis, Risk, BMJ Open, Pharmacokinetics, Vivo, Forward-looking statement, Longevity, Tumor necrosis factor, Genta (company), Serum, Intention, CMO, Sex, Death, Central nervous system, Multiple sclerosis, Immune system, Warfarin necrosis, Cytokine, Johns Hopkins School of Medicine, Traffic barrier, Cannabidiol, Sarcopenia, Pharmaceutical industry, Vaccine, CBD, MD

View the full release here: https://www.businesswire.com/news/home/20220803005056/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220803005056/en/
    We are very excited that this important early data with our lead product MYMD-1 has been published in a prestigious medical journal, said Chris Chapman, MD, President, Director, and CMO of MyMD Pharmaceuticals.
  • Our ongoing Phase 2 study of MYMD-1 in sarcopenia/frailty, a result of a pathological aging process, is going well.
  • The companys scientific advisory board met recently and agreed to move to the next higher dose in the study.
  • In vivo, a longitudinal cohort of C57BL/6 mice, was randomized to receive either MYMD-1, high-dose rapamycin, or low-dose rapamycin plus metformin.

Legend Capital Portfolio Company: The Global-Leading AI Medical Imaging Company Lunit Goes Public Successfully

Retrieved on: 
Jeudi, juillet 21, 2022
Regulation of tobacco by the U.S. Food and Drug Administration, UNPRI, Diagnosis, Investment, Physician, Philips, Food, CEO, MDSAP, Solution, Liquid biopsy, Artificial intelligence, KFDA, USD, KOSDAQ, Cancer, Certification, CE, KAIST, Immunotherapy, Helmy Eltoukhy, Medical device, FDA, Patient, Breast cancer, Efficiency, BioMaPS Institute for Quantitative Biology, Health, Engineering, ESG, Growth, GE Healthcare, VC, AI, RMB, Fujifilm, Unimed, Technology

Lunit SCOPE is an AI biomarker for immunotherapy, providing therapy response information that can critically affect treatment outcomes for cancer patients.

Key Points: 
  • Lunit SCOPE is an AI biomarker for immunotherapy, providing therapy response information that can critically affect treatment outcomes for cancer patients.
  • For the past 4 years, Lunit not only has produced world-leading AI medical solutions but also gained its commercial value achieving rapid topline growth.
  • Legend Capital has invested heavily in companies that integrate technology and the medical industry and has kept betting on AI medical sectors.
  • In addition to Lunit, Legend Capital has also invested in AI medical companies such as Xbiome, an AI microbiome drug development company; StoneWise, an AI drug R&D platform; Deepwise, an AI medical imaging company; BioMap, a biocomputing platform; Deep Informatics ++, an AI medical pathology diagnosis company; and Unimed, an AI brain diagnosis and treatment platform.

Use of BioMAP Platform to Assess Nutraceuticals Published in BioMed Central

Retrieved on: 
Jeudi, juin 23, 2022
Life, BioScience Research Collaborative, University, CRO, Drug discovery, Safety, Industry, Protein, Biomedicine, Neurodegeneration, Inflammation, Enzyme assay, Pharmacology, BioMaPS Institute for Quantitative Biology, University of Buckingham, Ion, Biomarker, Metabolism, Enzyme, G protein-coupled receptor, Institute, Platform, Toxicology, View, Knowledge, ADME, Multimedia, BMC, Medicinal plants, Eurofins Scientific

ST. CHARLES, Mo., June 23, 2022 /PRNewswire/ -- Eurofins Discovery, the leading brand with over 35 years of success providing a complete solution of products and services for drug discovery, announces a client publication advancing cognitive health research through use of the company's BioMAP® Human Phenotypic Profiling and Screening Platform and enzyme assays for neurotransmitter degradation.

Key Points: 
  • The BioMAP Diversity PLUS Panel can provide this key assessment while covering a broad range of tissue and disease biology.
  • Additional neurotransmitter metabolism enzyme assays from Eurofins Discovery helped identify specific effects of sage extract, with implications for cognitive performance.
  • In addition toin vitrosafety pharmacology strengths, we also offer a broad portfolio of over 3,500 drug discovery services and 1,800 products.
  • We support a variety of drug discovery targets such as GPCRs, Kinases, Ion Channels, Nuclear Hormone Receptors and other proteins & enzymes.

Use of BioMAP Platform to Assess Nutraceuticals Published in BioMed Central

Retrieved on: 
Jeudi, juin 23, 2022
Life, BioScience Research Collaborative, University, CRO, Drug discovery, Safety, Industry, Protein, Biomedicine, Neurodegeneration, Inflammation, Enzyme assay, Pharmacology, BioMaPS Institute for Quantitative Biology, University of Buckingham, Ion, Biomarker, Metabolism, Enzyme, G protein-coupled receptor, Institute, Platform, Toxicology, Knowledge, ADME, BMC, Medicinal plants, Eurofins Scientific

ST. CHARLES, Mo., June 23, 2022 /PRNewswire/ -- Eurofins Discovery, the leading brand with over 35 years of success providing a complete solution of products and services for drug discovery, announces a client publication advancing cognitive health research through use of the company's BioMAP® Human Phenotypic Profiling and Screening Platform and enzyme assays for neurotransmitter degradation.

Key Points: 
  • The BioMAP Diversity PLUS Panel can provide this key assessment while covering a broad range of tissue and disease biology.
  • Additional neurotransmitter metabolism enzyme assays from Eurofins Discovery helped identify specific effects of sage extract, with implications for cognitive performance.
  • In addition toin vitrosafety pharmacology strengths, we also offer a broad portfolio of over 3,500 drug discovery services and 1,800 products.
  • We support a variety of drug discovery targets such as GPCRs, Kinases, Ion Channels, Nuclear Hormone Receptors and other proteins & enzymes.

QureBio Ltd. to Showcase its Q-1802 Clinical Advances at 2022 ASCO Annual Meetings

Retrieved on: 
Mardi, mai 31, 2022
Inflammation, Capital, Shenzhen Capital Group, Medicine, CNY, Clinical trial, River, AM, FDA, Industry, CDT, Chicago Times-Herald race, Therapy, BioMaPS Institute for Quantitative Biology, Flour, Fine chemical

In animal model studies, Q-1802 demonstrates both superior anti-tumor activities and excellent safety profiles.

Key Points: 
  • In animal model studies, Q-1802 demonstrates both superior anti-tumor activities and excellent safety profiles.
  • It recruits multiple immune mechanisms to kill tumor cells, offering a novel therapeutic opportunity for Claudin18.2 positive solid tumors.
  • Q-1802 also exhibits robust physicochemical properties and superb productivity with titers exceeding 4 grams per liter.
  • QureBio Ltd. is a clinical-stage biopharmaceutical company focusing on innovative biopharmaceuticals for urgent and unmet clinical needs, such as the treatment of refractory cancers, inflammation and other serious disorders.